MA-GILLETTE
31.5.2023 15:31:33 CEST | Business Wire | Press release
Gillette (NYSE: PG), the world’s largest male grooming company and brand pioneer in gaming and esports, proudly announced the return of the highly anticipated Gillette Cup Featuring Fortnite, a two-day international gaming competition featuring a custom-built island in Fortnite. First played in February 2022, the inaugural Gillette Cup garnered over 300,000 viewing hours throughout the tournament. Back for its second year, the event kicks off on June 1, 2023, and will unite members of the Gillette Gaming Alliance as they compete against members of the global Fortnite community for $50,000 -- doubling the prize pool from last year. The Gillette Cup Featuring Fortnite is among one of the largest branded tournaments to date for the gaming community.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230531005178/en/
Gillette celebrates return of Gillette Cup Featuring Fortnite with all-star Gillette Gaming Alliance. (Photo: Business Wire)
The competition will be played on a revamped “Gillette Face-Off” island, a custom environment developed using Fortnite’s Creative toolset; this builds on the success of the island’s existing futuristic lab and mineshaft versions, which were first introduced in 2022. The custom branded Fortnite islands feature action-packed “Zero Build” gameplay and iconic Gillette products for a gaming experience as satisfying as a close shave. To compete in the “Gillette Face-Off” islands at any time, use island code 6674-8139-7577.
“The celebrated return of the Gillette Cup Featuring Fortnite is testament to our previous successes and deepening relationship with Gillette Gaming Alliance members to provide meaningful and impactful experiences to the gaming community,” explains Daniel Ordonez, Gillette Global Brand Franchise Leader. “We are looking forward to cheering on our Alliance members and engaging with Fortnite’s community – while, most importantly, meeting them where they thrive in a truly fun and authentic way.”
For the first time, viewers and fans worldwide can visit www.GilletteCup.com to check out the leaderboard and tune-in for real-time updates. Additionally, they will have the chance to win exclusive Gillette Gaming gear and products by visiting the newly launched website throughout the tournament.
Tournament Details – Competitive, Professional Sporting Event Style Format
The tournament will kick off with the Regionals Round, where eight (8) teams of “Duos,” representing eight (8) countries/regions will compete – totaling 64 teams and 128 players across the globe. Participants will represent Brazil, France, Germany, Italy, Mexico, Spain, United Kingdom, and USA/Canada. Using a points system, teams will be randomly placed on the “Gillette Face-Off” island and compete in multiple rounds of Zero Build matches.
The top 16 teams from Regionals will compete for the opportunity to advance to Semi-Finals and be divided into two (2) groups of eight (8) Duos. These 16 teams will continue to compete in multiple rounds of the “Gillette Face-Off” island. The top four (4) Duos from each group will advance to the Finals to form a single lobby and compete in multiple rounds of the Gillette Cup custom island. The Duos will be scored using the points system and awarded cash prizing, based on how they rank. The last Duo standing will be named winner of the Gillette Cup!
Gillette Gaming Alliance members – inclusive of TypicalGamer (USA/Canada), Vicens (Spain), Agustin (Spain), Papaplatte (Germany), Rumathra (Germany), Elded (Mexico), Jolavanille (France), Pizfn (Italy), Xuider (Italy), Mongraal (United Kingdom), and Nobru (Brazil) – will represent their respective countries as they battle it out against fellow professional members of the Fortnite community to bring home the “win” and championship prize.
“I have had a blast streaming for the Gillette Gaming Alliance this year and providing awesome content and experiences to my community on behalf of the brand,” shares Fortnite pro Andre Rebelo, also known as TypicalGamer, Gillette Gaming Alliance member representing North America. “I remember tuning into the Gillette Cup last year and thinking it was epic. So, I am really excited to be a part of it myself this year – and I hope to bring home the W for my fans and followers.”
The Gillette Gaming Alliance, now in its fifth year, serves as Gillette’s longest running gaming activation as well as one of the most defining and successful programs to date for the brand.
*This is an independently created Fortnite Creative experience and is not sponsored, endorsed, or administered by Epic Games, Inc.
About Gillette
For more than 120 years, Gillette has delivered precision technology and unrivaled product performance – improving the lives of over 800 million consumers around the world. From shaving and body grooming, to skin care and sweat protection, Gillette offers a wide variety of products including razors, shave gel (gels, foams and creams), skin care, after shaves, antiperspirants, deodorants and body wash. For more information and the latest news on Gillette, visit www.gillette.com. To see our full selection of products, visit www.gillette.com. Follow Gillette on Twitter, Facebook and Instagram.
About Procter & Gamble
P&G serves consumers around the world with one of the strongest portfolios of trusted, quality, leadership brands, including Always®, Ambi Pur®, Ariel®, Bounty®, Charmin®, Crest®, Dawn®, Downy®, Fairy®, Febreze®, Gain®, Gillette®, Head & Shoulders®, Lenor®, Olay®, Oral-B®, Pampers®, Pantene®, SK-II®, Tide®, Vicks®, and Whisper® The P&G community includes operations in approximately 70 countries worldwide. Please visit http://www.pg.com for the latest news and information about P&G and its brands. For other P&G news, visit us at www.pg.com/news.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230531005178/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom